Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 19/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 18/20 | 1.00 |
| ▸ | FLT1 | P17948 | 18/20 | 1.00 |
| ▸ | FLT4 | P35916 | 13/20 | 1.00 |
| ▸ | EGFR | P00533 | 12/20 | 1.00 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.72 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.72 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.72 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.72 |
| ▸ | AURKA | O14965 | 1/20 | 0.71 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.71 |
| ▸ | TEK | Q02763 | 1/20 | 0.71 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7867152 | 0.96 | KDR (0.98) | KDRFGFR1FLT1FLT4EGFR | |
| SCHEMBL1467998 | 0.95 | KDR (0.90) | KDRFGFR1FLT1FLT4EGFR | |
| Hydrochloric Acid SCHEMBL7864665 | 0.95 | KDR (1.00) | KDRFGFR1FLT1FLT4EGFR | |
| Hydrochloric Acid SCHEMBL1468148 | 0.94 | KDR (0.89) | KDRFGFR1FLT1FLT4EGFR | |
| SCHEMBL1467348 | 0.94 | FLT1 (1.00) | KDRFGFR1FLT1FLT4EGFR | |
| SCHEMBL1468063 | 0.92 | FLT1 (0.84) | KDRFGFR1FLT1FLT4EGFR | |
| SCHEMBL1467741 | 0.91 | FLT1 (0.85) | KDRFGFR1FLT1FLT4EGFR | |
| SCHEMBL7864646 | 0.91 | KDR (1.00) | KDRFGFR1FLT1FLT4EGFR | |
| Hydrochloric Acid SCHEMBL7870623 | 0.91 | KDR (0.98) | KDRFGFR1FLT1FLT4EGFR | |
| SCHEMBL7864675 | 0.90 | KDR (0.90) | KDRFGFR1FLT1FLT4EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0885198-B1 | 4-ANILINOQUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-12-19 | — | — | EP | claimed |
| US-6291455-B1 | PRODUCING AN ANTIANGIOGENIC AND/OR VASCULAR PERMEABILITY REDUCING EFFECT | ZENECA LIMITED (GB) | 2001-09-18 | — | — | US | claimed |
| EP-0885198-A1 | 4-ANILINOQUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1998-12-23 | — | — | EP | claimed |
| WO-1997032856-A1 | 4-ANILINOQUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1997-09-12 | — | — | WO | claimed |
| US-20240156825-A1 | USE OF SELECTIVE VEGFR2 AND FGFR1 INHIBITORS | FOUNTAIN THERAPEUTICS INC (US) | 2024-05-16 | — | — | US | disclosed |
| EP-0885198-B1 | 4-ANILINOQUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-12-19 | — | — | EP | disclosed |
| US-6291455-B1 | PRODUCING AN ANTIANGIOGENIC AND/OR VASCULAR PERMEABILITY REDUCING EFFECT | ZENECA LIMITED (GB) | 2001-09-18 | — | — | US | disclosed |
| EP-0885198-A1 | 4-ANILINOQUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1998-12-23 | — | — | EP | disclosed |
| WO-1997032856-A1 | 4-ANILINOQUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1997-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240156825-A1 | USE OF SELECTIVE VEGFR2 AND FGFR1 INHIBITORS | FGFR1, FRS2, FGFR2 | KDR 5/4885FGFR1 1/4885FLT1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.